IN RE: SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION
Case Number:
2:13-md-02445
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
-
February 28, 2024
Indivior's $385M Suboxone Antitrust Deal Gets Final OK
A Pennsylvania federal judge has granted final approval to Indivior's $385 million settlement with direct purchasers in antitrust litigation over its opioid addiction treatment Suboxone and awarded roughly $120 million in attorney fees to the purchasers' counsel.
-
October 23, 2023
Indivior Cuts $385M Deal To End Suboxone Antitrust Claims
Drugmaker Indivior Inc. said Monday that it had reached a $385 million settlement with direct purchasers in antitrust litigation over its opioid addiction treatment Suboxone, heading off a trial in multidistrict litigation that had been scheduled to begin Oct. 30.
-
September 06, 2023
Suboxone End Payor Attys Seek $12.5M In $30M Antitrust MDL
Five plaintiffs firms have asked a Pennsylvania federal court to award them $12.5 million of the $30 million settlement they recently struck in the Indivior Inc. multidistrict litigation, on behalf of a class of insurance plans suing the drugmaker for violating antitrust laws by jacking up the price of opioid addiction treatment Suboxone.
-
August 30, 2023
Suboxone Buyers Can't Narrow Product Market Ahead Of Trial
A Pennsylvania federal judge refused Wednesday to cordon off a Suboxone product market that would make it easier for wholesalers and other direct buyers of the opioid addiction treatment to show pharmaceutical company Indivior anti-competitively blocked potential competitors, leaving the exact market definition to a late October trial.
-
August 21, 2023
Indivior Cuts Suboxone Buyers $30M Deal In Antitrust MDL
Indivior Inc. and the class of end payors who accused it of monopolizing the market on Suboxone, an opioid addiction treatment, have agreed to resolve their dispute in a $30 million settlement agreement filed in the Pennsylvania federal court overseeing the multidistrict litigation surrounding the drug.
-
August 15, 2023
Antitrust Watchers Are About To Have Their Hands Full
A deluge of trials and key hearings are slated for the coming weeks in antitrust cases spread across the country, including the first expected trials for monopolization claims against Google, trials in a variety of other conduct cases from enforcers and private parties, and hearings on several merger challenges.
-
June 02, 2023
AGs Cut $102M Deal With Indivior In Suboxone Antitrust Case
More than three dozen state-level enforcers reached a $102.5 million deal on Friday with Indivior Inc. to resolve claims that the drugmaker monopolized the market for the opioid addiction treatment Suboxone ahead of a looming September trial.
-
May 30, 2023
Suboxone Buyers Fight Late Dismissal Bid In Antitrust Case
A class of end payors accusing Indivior of monopolizing the market for opioid addiction treatment Suboxone told a Pennsylvania federal court it already found they have standing to bring their claims and said there's no reason to toss them from the case now.
-
May 11, 2023
Indivior Wants Class Tossed From Suboxone Antitrust Case
Indivior urged a Pennsylvania federal court on Thursday to dismiss a class of end payors from a case accusing the company of monopolizing the market for the opioid addiction treatment Suboxone, arguing the end payors have never demonstrated how they "suffered any harm" from the alleged violations.
-
November 17, 2022
Indivior Spars With States, Suboxone Buyers Over Trial Date
State attorneys general and others accusing Indivior of monopolizing the market for the opioid addiction treatment Suboxone are asking for a trial in May or June of next year, but the company says it won't be ready until August.